Astrea Bioseparations Expands North American Facilities
Astrea Bioseparations (Cambridge, UK) has announced that it has expanded its manufacturing and warehousing capabilities in the US.
Team integration into a company. Joining specialists and professionals. Employment hiring workers. Human resources. New experience. Personel growth. Management appointment. New members | Image Credit: © Andrii Yalanskyi - stock.adobe.com
Located in Canton, Massachusetts, the 12,000-square-foot facility will expand the company’s US footprint and increase its workforce up to 9% over an 18‑month period. It will feature cleanroom laboratories for column packing services, offices, warehousing, and column assembly spaces.
“Expanding our presence in the US reflects growing demand for our chromatography products and services to support effective development and production of cutting-edge biologics, including cell and gene therapies,” said Chris Brown, operations director at Astrea Bioseparations. “The new site gives us greater capacity to support new and existing customers by providing innovative and high‑quality products, within market‑leading time frames, as well as offering local technical expertise.”
For more information, please visit: www.astreabioseparations.com
Analyzing Bone Proteins in Forensic Laboratories Using LC−MS/MS
November 4th 2024A recent study compared different workflows for extracting, purifying, and analyzing bone proteins using liquid chromatography with tandem mass spectrometry (LC–MS/MS), including an in-StageTip protocol previously optimized for forensic applications, and two protocols using novel suspension-trap technology (S-Trap) and different lysis solutions. LCGC International discussed this work with Noemi Procopio of the School of Law and Policing and the Research Centre for Field Archaeology and Forensic Taphonomy at the University of Central Lancashire (UK), corresponding author of the paper that resulted from this study.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Profiling Volatile Organic Compounds in Whisky with GC×GC–MS
November 1st 2024Researchers from Austria, Greece, and Italy conducted a study to analyze volatile organic compounds (VOCs) present in Irish and Scotch whiskys using solid-phase microextraction (SPME) Arrow with comprehensive two-dimensional gas chromatography coupled to mass spectrometry (GC×GC–MS) to examine the organoleptic characteristics that influence the taste of spirits.
